SAN DIEGO, October 29, 2015 – Profil Institute for Clinical Research, Inc., an early phase clinical research organization (CRO) focused on diabetes and obesity, looks forward to JDRF’s Walk to Cure Diabetes on Saturday, November 7 in Balboa Park. This year marks Profil Institute’s 11th year walking and fundraising as a corporate team of employees and supporters and also its 11th year as a corporate sponsor.
Type 1 diabetes is an autoimmune disease in which a person’s pancreas loses the ability to produce insulin — a hormone essential to turning food into energy. It strikes both children and adults suddenly and is unrelated to diet and lifestyle. It requires constant carbohydrate counting, blood-glucose testing, and lifelong dependence on injected insulin. With type 1 diabetes there are no days off, and there is no cure. That’s why JDRF holds more than 200 Walks across the country every year to raise money to support research efforts to find a cure.
“The event itself is truly inspirational when witnessing so many people and businesses united together for a cause as vitally important as finding a cure and better treatments for type 1 diabetes,” said Dr. Marcus Hompesch, Profil Institute President and CEO. “Profil Institute is proud to be teaming up with JDRF to support the type 1 diabetes community and its Walk to Cure Diabetes fundraising event here in San Diego.”
About Profil Institute for Clinical Research, Inc.
Profil Institute for Clinical Research, Inc. is a science driven, early phase clinical research organization (CRO) focused on diabetes and obesity. It is renowned for its scientific expertise, depth of services, expanded scope of research methodologies, and experience with every clinically relevant drug class in diabetes. The company provides end-to-end early phase services from consulting for strategic clinical development and regulatory planning through design and completion of complex clinical trials, including the reporting and publication of final study results.
Profil Institute’s expertise and experience encompasses small and large molecule therapies, biologics and biosimilars through all routes of administration, as well as devices. The company’s clients range from large pharma and drug discovery companies to small virtual companies throughout the Americas, Europe and Asia.
For further information, please contact: